Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience

Transplantation

Volumn 86, Issue 12, 2008, Pages 1725-1731

  Tan, Henkie P ^a   Donaldson, Joseph ^a   Ellis, Demetrius ^a   Moritz, Michael L ^a   Basu, Amit ^a   Morgan, Claire ^a   Vats, Abhay N ^a   Erkan, Elif ^a   Shapiro, Ron ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Acute cellular rejection; Antibody mediated rejection; Campath 1H; Induction; Laparoscopic live donor nephrectomy; Steroid avoidance; Steroid free

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; COTRIMOXAZOLE; CREATININE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; STEROID; TACROLIMUS; VALGANCICLOVIR; CANCER ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADD ON THERAPY; ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ARTERY THROMBOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LAPAROSCOPY; LIVING DONOR; LOW DRUG DOSE; MALE; MONOTHERAPY; NEPHRECTOMY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; REPEATED DRUG DOSE; SCHOOL CHILD; SURGICAL INFECTION; SURGICAL MORTALITY; TREATMENT OUTCOME; VEIN THROMBOSIS; VIREMIA; ADULT; BLOOD; CLASSIFICATION; FOLLOW UP; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY DISEASE; MORTALITY; REOPERATION; STATISTICS; SURVIVAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CHILD; CREATININE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; REOPERATION; SURVIVAL ANALYSIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 58849135828     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181903da7     Document Type: Article

References (52)

1. Murray JE, Merrill JP, Dammin GJ, et al. Kidney transplantation in modified recipients. Ann Surg 1962; 156: 337.
2. Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385.
3. Calne RY, White DJ, Pentlow BD, et al. Cyclosporin A: Preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants. Transplant Proc 1979; 11: 860.
4. Starzl TE, Todo S, Fung J, et al. FK 506 for human liver, kidney and pancreas transplantation. Lancet 1989; 2: 1000.
5. Starzl TE, Marchioro TL, Porter KA, et al. The use of heterologous antilymphoid agents in canine renal and liver homotransplantations and in human renal homotransplantations. Surg Gynecol Obstet 1967; 124: 301.
6. Starzl TE, Porter KA, Iwasaki Y, et al. The use of antilymphocyte globulin in human renal homotransplantations. In: Wolstenholme GEW, O'Connor M, eds. Antilymphocytic serum. London, J and A Churchill Limited 1967, pp 4.
7. Najarian JS, Simmons RL, Gewurz H, et al. Anti-serum to cultured human lymphoblasts: Preparation, purification and immunosuppressive properties in man. Ann Surg 1969; 170: 617.
8. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunological monitoring and treatment in recipients of renal allografts. N Eng J Med 1981; 305: 308.
9. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193.
10. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
11. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394.
12. Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol 2002; 19(suppl): 3.
13. Calne RY, Friend P, Moffatt S, et al. Prope tolerance perioperative campath-1H, and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
14. Calne R, Moffatt SD, Friend PJ, et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613.
15. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
16. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - Efficacy and safety at five years. Am J Transplant 2005; 5: 1347.
17. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80: 765.
18. Knechtle SJ, Pirsch JD, H Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722.
19. Barth RN, Janus CA, Lillesand CA, et al. Outcomes at three years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006; 19: 885.
20. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009.
21. Tan HP, Kaczorowski DJ, Basu A, et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: A single center preliminary experience. Transplantation 2004; 78: 1683.
22. Tan HP, Kaczorowski DJ, Basu A, et al. Steroid-free tacrolimus monotherapy following pretransplant thymoglobulin or Campath and laparoscopy in living donor renal transplantation. Transpl Proc 2005; 37: 4235.
23. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy Am J Transplant 2006; 6: 2409.
24. Tan HP, Marcos A, Shapiro R, eds. Living donor transplantation. New York, Informa Healthcare 2007.
25. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath. J Am Coll Surg 2005; 200: 505.
26. Shapiro R, Ellis D, Tan HP, et al. Antilymphoid antibody preconditioning with tacrolimus monotherapy for pediatric renal transplantation. J Pediatr 2006; 148: 813.
27. Shapiro R, Ellis D, Tan HP, et al. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. Am J Transplant 2007; 7: 2736.
28. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring1. Transplantation 2005; 80:457.
29. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney trans- plantation: Comparison with basiliximab induction - Long-term results. Am J Transplant 2005; 5: 2539.
30. Kaufman DB, Leventhal JR, Gallon LG, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - Long-term results. Am J Transplant 2006; 6: 331.
31. Knechtle SJ, Fernandez LA, Pirsch JD,etal. Campath-1Hinrenal transplantation: The University of Wisconsin experience. Surgery 2004; 136: 754.
32. Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. Am J Transplant 2005; 5: 1569.
33. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation 2006; 81: 1361.
34. Ciancio G, Burke GW. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8: 15.
35. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
36. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trialof HLA and MICA antibodiesonkidney graft survival. Am J Transplant 2007; 7: 864.
37. Shapiro R, Zeevi A, Basu A, et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donorspecific antibody. Transplantation 2008; 85: 1125.
38. Ryan CM, Swanson DP. Clinical research, innovative practice and IRB review: Identifying and respecting boundaries. Am J Transplant 2007; 7: 748.
39. Tan HP, Maley WR, Kavoussi LR, et al. Laparoscopic live donor ne-phrectomy: Evolution of a new standard. Curr Opin Organ Transplant 2000; 12: 312.
40. Nankivell BJ, Borrows RJ, Fung CL, etal. The natural historyof chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
41. Starzl TE, Zinkernagel R. Transplantation tolerance from a historical perspective. Nat Rev Immunol 2001; 1: 233.
42. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosup-pression for organ transplantation. Lancet 2003; 361: 1502.
43. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003; 238: 520.
44. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacroli-mus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation 2006; 82: 1621.
45. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465.
46. Bloom DD, Hu H, Fechner JH, et al. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006; 81: 81.
47. Knechtle SJ. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr Transplant 2004; 8: 106.
48. Faderl S, Coutre S, Byrd JC, et al. The evolving role of alemtuzumab in management of patients with CLL. Leukemia 2005; 19: 2147.
49. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005; 80: 1051.
50. US Scientific Registry of Transplant Recipients Annual report 2006. Available at: http://www.ustransplant.org. Accessed August 1, 2008.
51. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation.N Engl J Med 2002; 346: 580.
52. Kasiske BL, Vazquez MA, Harmon WE,etal. Recommendations for the outpatient surveillance ofrenal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11(suppl 15): S1.